Please enter exact key words
Anti-GRP132 Monoclonal Antibodies

for the Treatment of Pancreatic Cancer

Home / Available Projects / Anti-GRP132 Monoclonal Antibodies
Drug Name GPCR-targeted Project 011

A monoclonal antibody agonist the G -protein coupled receptor G2A (GRP132) is being developed for the treatment of pancreatic cancer and pancreatic cancer ductal adenocarcinoma. GPR132 is a novel member of GPCRs.

Target G-protein coupled receptor G2A (GRP132)
Drug Modality Monoclonal antibody
Indication Pancreatic cancer
Product Category Biologic
Mechanism of Action G protein-coupled receptor agonists
Status Discovery
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.